All In Biotech

Drug Trial Radar · NCT00001993

Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3

Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

120

Actual

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
G D SearleIndustry
Sponsor type
Industry
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the preliminary efficacy and tolerability of combining a selected dose of SC-48334 with low-dose AZT in the treatment of symptomatic HIV+ patients with 200 to 500 CD4+ cells/mm3. The secondary objective is to determine the pharmacokinetics and bioavailability of both SC-48334 and AZT, when administered together, in symptomatic HIV+ patients with 200 - 500 CD4+ cells/mm3.

Conditions

  • HIV Infections

Interventions

  • ButyldeoxynojirimycinDrug

  • ZidovudineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Univ of Miami School of Medicine

    Miami, Florida

  • Rush Presbyterian - Saint Luke's Med Ctr

    Chicago, Illinois

  • Infectious Diseases Research Clinic / Indiana Univ Hosp

    Indianapolis, Indiana

  • Ohio State Univ Hosp Clinic

    Columbus, Ohio

  • Julio Arroyo

    West Columbia, South Carolina

  • Univ of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.